Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Disease-modifying therapy in multiple sclerosis: strategies for optimizing management.

Elliot Frohman1, Ted Phillips, Kristen Kokel

  • 1Department of Neurology, University of Texas Southwestern Medical Center at Dallas, 75235, USA. elliot.frohman@utsouthwestern.edu

The Neurologist
|June 14, 2003
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Practical Clinical Guidelines for Natalizumab Treatment in Patients With Relapsing Multiple Sclerosis.

Journal of infusion nursing : the official publication of the Infusion Nurses Society·2023
Same author

Recurrent Optic Neuritis and Perineuritis Followed by an Unexpected Discovery: From the National Multiple Sclerosis Society Case Conference Proceedings.

Neurology(R) neuroimmunology & neuroinflammation·2022
Same author

Precision Terminology: Why to Avoid the Term "Atypical Optic Neuritis".

Neurology·2022
Same author

Diagnosis and classification of optic neuritis.

The Lancet. Neurology·2022
Same author

The Role of Optical Coherence Tomography Criteria and Machine Learning in Multiple Sclerosis and Optic Neuritis Diagnosis.

Neurology·2022
Same author

Defining Clinical and Immunological Predictors of Poor Immune Responses to COVID-19 mRNA Vaccines in Patients with Primary Antibody Deficiency.

Journal of clinical immunology·2022

Managing multiple sclerosis (MS) with disease-modifying agents (DMAs) presents challenges. Practical strategies can mitigate adverse reactions and improve patient compliance for long-term treatment success.

Area of Science:

  • Neurology
  • Immunology

Background:

  • Multiple sclerosis (MS) treatment involves disease-modifying agents (DMAs).
  • Patients and providers face challenges in DMA therapy utilization.
  • Adverse reactions and treatment compliance are key concerns.

Purpose of the Study:

  • To highlight challenges in multiple sclerosis (MS) disease-modifying agent (DMA) therapy.
  • To offer practical management strategies for adverse reactions and compliance.
  • To enhance long-term treatment adherence in MS patients.

Main Methods:

  • Review of clinical experience with 5000 MS patients.
  • Focus on interferon beta1a, interferon beta1b, and glatiramer acetate.
  • Development of an assessment and intervention instrument for clinic and telephone use.

Related Experiment Videos

Main Results:

  • Interferon beta and glatiramer acetate are primary DMAs for relapsing MS in the US.
  • Clinical experience informs strategies to manage treatment challenges.
  • An assessment and intervention tool aims to improve compliance and minimize adverse events.

Conclusions:

  • A comprehensive approach optimizes MS patient management.
  • Effective strategies address challenges in DMA therapy utilization.
  • Mitigating adverse reactions and enhancing compliance are crucial for successful MS treatment.